Pasithea Therapeutics
KTTA
12 hedge funds and large institutions have $184K invested in Pasithea Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
9% more funds holding
Funds holding: 11 → 12 (+1)
0.13% more ownership
Funds ownership: 1.32% → 1.45% (+0.13%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
8% less capital inflows, than outflows
Capital inflows: $27.7K | Capital outflows: $30K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
+$16.6K |
| 2 |
Jane Street
New York
|
+$5.99K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.79K |
| 4 |
Renaissance Technologies
New York
|
+$1.5K |
| 5 |
Virtu Financial
New York
|
+$831 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$15.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$9.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.42K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$48 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$3 |
KTTA Hedge Fund Activity: Q2 2023 in Review
12 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q2 2023, worth a combined $184K — up 25% from $148K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new KTTA positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $16.6K. The largest seller was Vanguard Group, cutting an estimated $15.8K.
- 12 institutional investors held Pasithea Therapeutics (KTTA) as of Q2 2023, up from 11 in Q1 2023.
- Funds reported $184K of Pasithea Therapeutics stock for Q2 2023, up 25% quarter-over-quarter.
- 3 funds opened new Pasithea Therapeutics positions in Q2 2023 and 2 closed out, a net change of +1 holder.
- The largest Pasithea Therapeutics buyer in Q2 2023 was HRT Financial, an estimated $16.6K added.
- The largest Pasithea Therapeutics seller in Q2 2023 was Vanguard Group, an estimated $15.8K sold.
Based on aggregated 13F filings for Q2 2023.